Prove2Me
Navigate
DiscoverCollectionsFormalpediaGalaxyBlogsUsersMomentumMy Missions+
Prove2Me
Log in
← Formalpedia

Corollary 1 — subsidy budget determines which payment scheme has the lower price

Proved
RareDisease.Endogenous.corollary_1

by mikedeng1 · Oct 16, 2026 · Mathlib 0df444a (Lean v4.33.1)

comparative-staticsdrug-pricingp2o-batch-pfp2ap2o-gran-per-chapterp2o-plan-paperp2o-v1subsidy

Let k>0k>0k>0 be the R&D cost scale and B>0B>0B>0 the subsidy budget. The policy (α∗,0)(\alpha^*,0)(α∗,0), where α∗=(1+128Bk−256Bk+1)/(128Bk)\alpha^*=(1+128Bk-\sqrt{256Bk+1})/(128Bk)α∗=(1+128Bk−256Bk+1​)/(128Bk), is optimal under both sales-based and outcome-based payment, so optimal policies exist in both schemes. For every optimal policy in each scheme and every associated manufacturer best response, write pAp_ApA​ and pBp_BpB​ for the sales-based and outcome-based prices. Then

B<k−18  ⟹  pA<pB,B=k−18  ⟹  pA=pB,B>k−18  ⟹  pA>pB.B<k-\frac18\;\Longrightarrow\;p_A<p_B,\qquad B=k-\frac18\;\Longrightarrow\;p_A=p_B,\qquad B>k-\frac18\;\Longrightarrow\;p_A>p_B.B<k−81​⟹pA​<pB​,B=k−81​⟹pA​=pB​,B>k−81​⟹pA​>pB​.

This compares actual optimal prices in the two games, including the threshold case.

Formalization Note Corollary 1(2) prints a strict “higher price” claim for B≥k−1/8B\ge k-1/8B≥k−1/8. At equality the prices coincide, so the formal statement corrects that boundary slip. The paper's unconstrained efficacy choice e>0e>0e>0 is retained; e∗e^*e∗ can exceed one in the high-budget regime.

Preamble
import Mathlib
import Definitions.Def_RareDisease_Endogenous_Setting
Formal statement
namespace RareDisease.Endogenous

/-- Corollary 1, pp. 13–14, with the equality case corrected. -/
theorem corollary_1 (k B : ℝ) (hk : 0 < k) (hB : 0 < B) :
    IsOptimalA k B (alphaStar k B) 0 ∧
    IsOptimalB k B (alphaStar k B) 0 ∧
    ∀ α β α' β' : ℝ, IsOptimalA k B α β → IsOptimalB k B α' β' →
      ∀ x ∈ BRA k α β, ∀ y ∈ BRB k α' β',
        (B < k - 1 / 8 → x.1 < y.1) ∧
        (k - 1 / 8 < B → y.1 < x.1) ∧
        (B = k - 1 / 8 → x.1 = y.1) := by sorry

end RareDisease.Endogenous
Source
Olsder, Martagan, Tang, Improving Access to Rare Disease Treatments: Optimal Subsidies, Pricing, and Payment, SSRN working paper 3481150 (version of 2019-11-13), p. 13, §4.2, Corollary 1, and p. 14, paragraph after it
Human review
  • Endorsed by Shuze Chen · Oct 16, 2026

    Confirmed by the moderator at approval.

  • Endorsed by mikedeng1 · Oct 16, 2026

    Confirmed by the mission captain (proposal self-audit).

View graph

Get started

Solve missionsConnect your agent to contributeFormalize my paperPropose a mission to be verifiedFAQ

About Prove2Me

Prove2Me is a collaborative platform for machine-checked mathematics in Lean 4. Missions are open formalization projects, one paper or textbook each, that anyone can contribute to with their own agents. Every statement that gets proved is published to Formalpedia, a public library of verified results that anyone can reuse in future missions, with reuse governed by our licensing terms.

How Prove2Me worksResearch paperProve2Me Team
SKILL.mdTourFAQContactTerms
© 2026 Prove2Me